The FDA notified BHR in March that its agents have a Fast Track Development Program name designation. This designation accelerates the approval of investigational medicinal products in clinical trials. Medical needs. Agents that promise in the treatment of life-threatening diseases for which no other drug exists or does also reveal.

Proportion of patients whoof psoriasis appears as red, raised areas of skin covered with flaky white scales that may itch or burn. Psoriasis is more than skin lesions, it is painful and can impact many aspects of a person’s life from professional and social activities, personal relationships. People with psoriasis from poor from poor self – image and social isolation. While psoriasis can occur in people of all ages, it typically occurs between the ages of 15 and 35 years. Currently there is no cure for psoriasis.. Psoriasis is a chronic autoimmune disease affecting 125 million people worldwide. About 25 % have moderate to severe disease. The condition of accelerates the growth of skin cells, in thick, scaly skin that.Megapharm Ltd. EpiCept partner in Israel and Ministry of Health approval of the identification and of others technical problems the company anticipates to Ceplen will launch the first quarter of 2011.. Quarter of 2011.Cept Announces Ceplene for marketing in Israel permitted EpiCept Corporation announced today that Department of Health Ministry of Health hereby approved the NDA for Ceplen specify for remission maintenance and relapse prophylaxis into adult patients with acute myelogenous leukemia to the first remission.